Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy

AIDS

Volumn 14, Issue 8, 2000, Pages 959-969

  Kaufmann, Gilbert R ^a   Bloch, Mark ^b   Zaunders, John J ^c   Smith, Don ^a   Cooper, David A ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Holdsworth House General Practice   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

CD4; CD8; Highly active antiretroviral therapy (HAART); HIV; HIV RNA; Immune reconstitution; T lymphocytes

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD LEVEL; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034119250     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005260-00007     Document Type: Article

References (26)

1. 1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
2. 2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
3. 3. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
4. 4. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528-1533.
5. 5. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998, 280:35-41.
6. 6. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engt J Med 1996, 334:1011-1017.
7. 7. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
8. 8. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
9. 9. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
10. 10. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
11. 11. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998, 188:83-91.
12. 12. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
13. 13. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
14. 14. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
15. 15. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998, 177:898-904.
16. 16. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997, 315:1194-1199.
17. 17. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
18. 18. Fleming P, Ward J, Karon J, Hanson D, De Cock K. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998, 12:S55-S61.
19. 19. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3: 533-540.
20. 20. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:318-326.
21. 21. Staszewski S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999, 13:951-956.
22. 22. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999, 13:669-676.
23. 23. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999, 340:1301-1306.
24. 24. Zaunders J, Cunningham P, Kelleher A, et al. Potent antiretroviral therapy of primary HIV-1 infection: partial normalization of T lymphocyte subsets and limited reduction of proviral DNA despite clearance of plasma viremia. J Infect Dis 1999, 180:320-329.
25. 25. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12:745-750.
26. 26. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723-724.